Compendium of Cancer Genome Aberrations

CNS5:Diffuse leptomeningeal glioneuronal tumour: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
gene rearrangements
individual region genomic Gain/Loss/LOH
Line 107: Line 107:
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
!Clinical Relevance Details/Other Notes
!
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|1p
7
|Loss
|<span class="blue-text">EXAMPLE:</span> Loss
|Complete arm loss (PMIDs: 22941225, 29766299)
|<span class="blue-text">EXAMPLE:</span>
|Chr1p
chr7
|Unknown
|<span class="blue-text">EXAMPLE:</span>
|D
Unknown
|Yes (WHO)
|<span class="blue-text">EXAMPLE:</span> D, P
|Prevalence common, between 59% (by FISH; PMIDs: 22596013,  17184079, 19486008, 22941225, 25720745) and 100% (by CNV calling from DNA methylation  array data; PMID: 29766299).
|<span class="blue-text">EXAMPLE:</span> No
|<span class="blue-text">EXAMPLE:</span>
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|1q
8
|Gain
|<span class="blue-text">EXAMPLE:</span> Gain
|Complete arm gain (PMIDs: 29766299, 30465258)
|<span class="blue-text">EXAMPLE:</span>
|Chr1q
chr8
|Unknown
|<span class="blue-text">EXAMPLE:</span>
|D
Unknown
|Yes (WHO)
|<span class="blue-text">EXAMPLE:</span> D, P
|Prevalence common, between 56% and 63% (by CNV calling from DNA methylation  array data; PMIDs: 29766299, 30465258)
|
 
|<span class="blue-text">EXAMPLE:</span>
Found in all cases of DLGNT methylation class (MC)-2 (PMID: 29766299)
Common recurrent secondary finding for t(8;21) (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
| colspan="8" |
17
|<span class="blue-text">EXAMPLE:</span> Amp
|<span class="blue-text">EXAMPLE:</span>
17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
|<span class="blue-text">EXAMPLE:</span>
''ERBB2''
|<span class="blue-text">EXAMPLE:</span> D, P, T
|
|<span class="blue-text">EXAMPLE:</span>
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
|-
|
|
|
|
|
|
|
|}
|}


Line 284: Line 263:
[[Category:DISEASE]]
[[Category:DISEASE]]
[[Category:Diseases D]]
[[Category:Diseases D]]
<references />
Retrieved from "https://test.ccga.io/index.php/CNS5:Diffuse_leptomeningeal_glioneuronal_tumour"